ÂÜÀòÂÒÂ×

Dorthe da Graça Thrige has extensive experience in the pharmaceutical industry. In 2020, they began working as Senior Project Director at Cantargia AB, a fast-growing publicly listed Swedish biotechnology company. Her main responsibilities included clinical development/management of clinical studies on nadunolimab (CAN04), heading Cantargia's New Projects group, and imaging in clinical development. From 2017 to 2020, they worked as Chief Operating Officer at Ascelia Pharma AB, an oncology-dedicated drug development company. Her main responsibilities included regulatory affairs, clinical development, and drug development. From 2012 to 2017, they worked at CMC Contrast AB (now Ascelia Pharma AB) in two roles: Chief Operating Officer and Vice President, Clinical & Regulatory Affairs. Her main responsibilities included drug development, regulatory affairs, and clinical development of Mangoral (CMC-001). From 2000 to 2012, they worked at Active Biotech AB in four roles: Director of Development, Head of Project Management and Scientific Project Manager, Head of Drug Discovery, and Scientific Project Manager. Her main responsibilities included project management of a lead optimization project, project manager of a target identification project, and drug development. From 1999 to 2000, they worked as a Research Scientist at AstraZeneca R&D. From 1998 to 1999, they worked as Head of Analytical Control at Pharmacia & Upjohn Hillerød AS (now MEKOS Laboratories AS). Her main responsibilities included development and manufacture of TRUE Test, a diagnostic contact allergy product, and new formulations of nicotine. From 1997 to 1998, they worked as Research Assistant Professor at the University of Copenhagen, where their main responsibilities included development of a D-Asp uptake in vitro rat assay and testing of potency of D-Asp uptake inhibitors.

Dorthe da Graça Thrige's education history began in 1983 when they attended Favrskov Gymnasium and earned their High School degree/matematisk studentereksamen in 1986. Dorthe then attended Københavns Universitet - University of Copenhagen from 1987 to 1992, where they obtained their MSc (Pharm). In 1992, they returned to Københavns Universitet - University of Copenhagen and completed their PhD in Structural medicinal chemistry in 1997. In 2010, they attended Lund University for Business Administration and Management.